Powerful Leadership Transition to Optimize Highly Promising AI Platform RenovaroCube for Multi-Cancer Early Detection & Monitoring: Stock Symbol: RENB

LOS ANGELES - PrZen -- Realignment to Optimize & Commercialize RenovaroCube, Disruptive AI Platform for Multi-omics Diagnostics for Cancer Early Detection and Patient Monitoring from Liquid Biopsies.

New Board Encompass Seasoned Veterans from Capital Markets, Governance, AI, Biotechnology, Cancer Detection and Treatment.

Restructuring to Accelerate Growth, Commercialization, Access to Strategic Capital and Create Long-Term Value for Shareholders.

Renovaro, Inc. (Stock Symbol: RENB) aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. RENB includes RenovaroBio with its advanced cell-gene immunotherapy company and RenovaroCube.

RENB RenovaroCube has developed an award-winning AI platform that is committed to the early detection of cancer and its recurrence and monitoring subsequent treatments. RenovaroCube intervenes at a stage where potential therapy can be most effective.

Strategic Restructuring and Leadership Transition
On October 16th RENB announced a strategic restructuring and leadership transition of senior management and the Board of Directors to realign resources focused on the Company's AI Platform, RenovaroCube for multi-cancer early detection and patient monitoring. The RENB Board, with the support of a supermajority of shareholders, appointed David Weinstein as director and new CEO and four new directors – Maurice van Tilburg, Chairman, Douglas Calder, James A. McNulty CPA, and Mark A. Collins PhD.

RENB new leadership led by David Weinstein, CEO, renowned senior Wall Street executive with 39 years in banking & analyst roles, recognized for developing dynamic growth strategies for a broad range of private and public companies with a focus on maximizing the value of innovative life science platforms.

RENB CEO David Weinstein commented, "The new five-member board is led by the new Chairman, Maurice van Tilburg, former CEO of Euronext Amsterdam and Director at the Netherlands National Growth Fund". Maurice brings a wealth of experience in Corporate Governance, operations, and product development critical to executing on RenoVision 2.0. Moreover, he is based in Amsterdam to assist our AI driven early cancer detection program at RenovaroCube."

Mr. Weinstein continued, "The rest of our experienced Board of Directors includes: James A. McNulty: after a 26 year-career as founder of three CPA firms, Mr. McNulty has served as CFO of several publicly traded Biopharmaceutical companies including 15 years at BioDelivery Sciences International.Douglas W. Calder: For the last 24 years Mr. Calder has served in a number of senior life science executive roles with a focus on cancer immunotherapy and is currently co-founder and president of Vycellix Inc., a company developing cell-based therapeutics, headquartered in Tampa, Florida at the Moffitt Cancer Center with scientific operations in Stockholm, Sweden on the Karolinska Institute campus.Mark A Collins, PhD: co-founded three companies in drug discovery, artificial intelligence, and the software space. Mark has strong knowledge of commercializing products and platforms in oncology diagnostics."

RENB Revitalized Commitment to "Ambitious Innovation" Includes:

1) Strategic Asset Review & Pipeline Prioritization.

2) Commitment to Develop RENB RenovaroCube as Best-in-Class Platform, while Securing World-Class Enabling Partnerships (Corporate & Academic).

3) Optimizing, Enhancing & Accelerating Cell Therapy Pipeline Clinical Advancement.

4) Financial Initiatives to Ensure the RENB Balance Sheet Strength in Tandem with Fiscal Responsibility including Strict Budget Discipline.

5) Synchronizing All Aspects of RRNB Business Units to Yield Maximum Benefits to Patients and Shareholders.

Independent Expert Assessment Validates RENB RenovaroCube's Potential as a Groundbreaking AI Platform Starting with Early Cancer Detection

Assessment by specialist AI team from "PersonalAIze" Highlights the Strength, Potential, and Visionary Talent Behind the Innovative Software as a Service (SaaS) Platform

On September 19th RENB announced thart PersonalAIze, a cutting-edge company in AI and machine learning applications for healthcare, has conducted a comprehensive evaluation of the RENB RenovaroCube's advanced AI platform. This effort is spearheaded by PersonalAIze CEOs and AI experts, Mark Hoogendoorn and Sandjai Bhulai, who bring their extensive expertise to assess the platform developed under the guidance of Frank van Asch, CTO and co-Founder of the technology on which the RENB RenovaroCube is based.

Advancing AI models by leveraging the latest state-of-the-art techniques.

Selecting optimal patient groups for data collection and evaluating models and final products in clinical settings.

Company Websites: www.renovarobio.com and  https://www.compasslivemedia.com/renb/

Media Contact
Company Name: Renovaro Inc.
Contact Person: David Weinstein, CEO
Email: ir@renovarobio.com
Phone:  732-780-5036
Home Country: United States

Disclaimer and Disclosure: www.aibrandnetwork.com